Trial Profile
An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of ProQuad When Administered by Intramuscular (IM) Route or Subcutaneous (SC) Route to Healthy Children Aged 12 to 18 Months
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs MMR-varicella zoster virus vaccine (Primary) ; MMR-varicella zoster virus vaccine (Primary)
- Indications Chickenpox; Measles; Mumps; Rubella
- Focus Pharmacodynamics
- Sponsors Merck Sharp & Dohme Corp.; sanofi pasteur MSD
- 01 Jul 2008 Actual end date changed from 1 May 07 to 1 January 2008, reported by Clinicaltrals.gov.
- 27 Oct 2007 Status changed from in progress to completed.
- 01 Mar 2007 New trial record.